Cullinan Management, Inc. CGEM 深 滬
等待開盤 07-22 09:30:00 美东时间
7.52
-0.010
-0.13%
華盛通- 最 高7.82
- 今 開7.55
- 成交量 16.72万股
- 最 低 7.48
- 昨 收 7.53
- 總市值 4.44亿
- 52周最高 20.365
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.85
- 委 比 -85.37%
- 總股本 5901.47万
- 歷史最高 59.85
- 量 比 0.69
- 振 幅 4.52%
- 歷史最低 6.85
- 每 手 1
- 風險率 4.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Stifel Reinstates Buy on Cullinan Therapeutics, Announces $22 Price Target
Stifel analyst Alex Thompson reinstates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and announces $22 price target.
06-11 23:48
思诺金医药助力智翔金泰与Cullinan就BCMA/CD3项目达成超7亿美元海外授权合作协议
在本次独家许可交易中，思诺金医药任智翔金泰的BD顾问，提供了全程商务服务。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhi...
06-05 20:53
思诺金医药助力智翔金泰与Cullinan就BCMA/CD3（GR1803）项目达成超7亿美元海外授权合作协议
原标题：思诺金医药助力智翔金泰与Cullinan就BCMA/CD3（GR1803）项目达成超7亿美元海外授权合作协议 来源：投资界综合 6月5日，智翔金泰（...
06-05 17:00
智翔金泰：与Cullinan就GR1803注射液签署授权许可与商业化协议
6月5日，智翔金泰（688443）公告称，公司与Cullinan Therapeutics, Inc.（纳斯达克股票代码：CGEM；以下简称“Cullinan”）签署授权许可与商业化协议，就GR1803注射液达成独家许可与合作协议。根据协议，Cullinan将获得GR1803 注射液除大中华区域以外区域的开发、生产、商业化权益，智翔金泰保留大中华区域所有适应症权益。
06-05 10:00
总金额超7亿美元！智翔金泰与Cullinan Therapeutics就GR18...
6月5日，智翔金泰（股票代码：688443）宣布，与纳斯达克上市公司Cullinan Therapeutics,Inc.（纳斯达克股票代码：CGEM；以下简称...
06-05 08:54
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
Cullinan Therapeutics与Genrix Bio达成协议，获得velinotamig的全球（除大中华区）独家许可，用于自身免疫性疾病开发。Velinotamig是一种BCMAxCD3双特异性T细胞接合剂，在复发/难治性多发性骨髓瘤中展现出潜在同类最佳疗效。Cullinan计划利用Genrix Bio的临床数据加速全球开发，预计现金储备支持至2028年。
06-04 20:02
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
Cullinan Therapeutics announced that its management will host an event at the 2025 ASCO Annual Meeting in Chicago and participate in the Jefferies Global Healthcare Conference in New York. The event includes a presentation on the Phase 2b REZILIENT1 trial of zipalertinib and panel discussions on cell therapy and autoimmune diseases. Webcasts will be available on the company’s investor website.
05-29 11:00
Cullinan Therapeutics And Taiho To Present Phase 2b Results From REZILIENT1 Trial Of Zipalertinib In Previously Treated EGFR ex20ins NSCLC At ASCO 2025
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2
05-23 05:33
Analysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Cullinan Management (CGEM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
05-12 21:50
